Suite 325, Rockville, Maryland 20852–3804; telephone: 301/435–4478; fax: 301/402–0220. A signed Confidentiality Agreement (CDA) will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patents and patent applications describe and claim compositions and methods that incorporate or are derived from the molecule known as alpha platelet derived growth factor receptor (α-PDGFR). α-PDGFR is also known as CD140a/PDGFRA/PDGF2/PDGFR-α. PDGFR-α is a type III receptor tyrosine kinase characterized by an extracellular domain having five IgG-like domains, a transmembrane domain and a catalytic intracellular domain. Research suggests it has autocrine and paracrine signaling capability. PDGFRA expression and signaling have been linked to tumorigenesis and its activity, although not always coupled with over-expression, has been implicated in a number of cancers including lung cancer, ovarian cancer, prostate cancer, glioblastoma and melanoma.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (*i.e.*, a completed ''Application for License to Public Health Service Inventions'') in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and/or objections filed in response to the notices of January 27, 1993 [58 FR 6287] and February 15, 1994 [59 FR 7259] are not considered responsive to this notice and will not be treated as objections thereto. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 5 U.S.C. 552.

Dated: August 18, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 04–19538 Filed 8–25–04; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Co-Exclusive License: Zenapax (Humanized Antibody Against the IL–2 Receptor Alpha Chain) as a Novel Treatment for Multiple Sclerosis

AGENCY: National Institutes of Health, Public Health Services, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a co-exclusive license to practice the inventions embodied in U.S. Provisional Patent Application No. 60/393,021, filed June 28, 2002, ''Method of Treating Autoimmune Diseases with Interferon-Beta and IL–2R Antagonist'' (DHHS ref. no. E–143–2002/0–US–01), International Patent Application No. PCT/US2002/038290, filed November 27, 2002, International Publication No. WO 2004/002500 A1, published January 8, 2004, ''Method of Treating Autoimmune Diseases with Interferon-Beta and IL–2R Antagonist'' (DHHS ref. no. E–143–2002/0–PCT–02), International Application No. PCT/US2003/020428, filed June 27, 2003, International Publication No. WO 2004/002421 A2, published January 8, 2004, ''Method For the Treatment of Multiple Sclerosis'' (DHHS ref. no. E–143–2002/0–PCT–04), and U.S. Patent Application No. 10/607,598, filed June 27, 2003, Publication No. US 2004/0109859 A1, published June 10, 2004, ''Method For the Treatment of Multiple Sclerosis'' (DHHS ref. no. E–143–2002/0–US–03), and all corresponding foreign patent applications to Serono S.A., of Geneva, Switzerland. The patent rights in these inventions have been assigned to the United States of America. This notice is a modification of a notice published in the **Federal Register** in 68 FR 70826–70827, Dec. 19, 2003.

The prospective co-exclusive license territory will be worldwide. The field of use may be limited to the treatment of multiple sclerosis using monoclonal antibodies against the interleukin-2 receptor. Two co-exclusive licenses may be granted.

DATES: Only license applications which are received by the National Institutes of Health on or before October 25, 2004 will be considered.

ADDRESSES: Requests for information, inquiries, comments, and other materials relating to the contemplated co-exclusive license should be directed to: Thomas P. Clouse, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: 301–435–4076; Facsimile: 301–402–0220; E-mail: *clouset@mail.nih.gov.* Copies of the international publications can be obtained from *http://ep.espacenet.com.* Copies of the U.S. publication can be obtained from *http://www.uspto.gov.*

SUPPLEMENTARY INFORMATION: The above-identified patent applications relate to the discovery that administration of an interleukin-2 receptor antagonist to a patient is effective in the treatment of autoimmune disorders. Examples in the patent applications show that a humanized antibody to the interleukin-2 receptor alpha chain (IL–2Rα) (humanized anti-Tac antibody), daclizumab, is effective in treating MS. In particular, it has been discovered that patients who failed to respond to therapy with interferon-beta showed dramatic improvement when treated with daclizumab, with patients showing both a reduction in the total number of lesions and cessation of appearance of new lesions during the treatment period. Pending claims in the above-referenced patent applications are directed to methods of treating a patient with multiple sclerosis (MS) by administering a therapeutically effective amount of an IL–2 receptor antagonist. IL–2 receptor antagonists can be antibodies, peptides, chemical compounds, and small molecules.

The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated co-exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 18, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04–19536 Filed 8–25–04; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Border and Transportation Security; Notice to Aliens Included in the United States Visitor and Immigrant Status Indicator Technology System (US–VISIT)

AGENCY: Border and Transportation Security Directorate, DHS.

ACTION: Notice; technical correction.

SUMMARY: On August 20, 2004, the Department of Homeland Security (DHS) published a Notice in the **Federal Register** at 69 FR 51695 adding certain ports to, and deleting certain ports from, inclusion in the US–VISIT program. In this Notice, the Jacksonville sea port in Jacksonville, Florida was inadvertently deleted. This technical correction amends the list of ports that was published on August 20, 2004 to include the Jacksonville sea port.

EFFECTIVE DATE: This Notice is effective August 26, 2004.

FOR FURTHER INFORMATION CONTACT: Michael Hardin, Program Analyst, US–VISIT, Border and Transportation Security, Department of Homeland Security, 425 I Street, NW., Washington, DC 20536, telephone (202) 298–5200.

SUPPLEMENTARY INFORMATION: On January 5, 2004, DHS published a Notice in the **Federal Register** at 69 FR 482 designating 115 airports and 14 sea ports for inclusion in the US–VISIT program. One of these 14 sea ports was the Jacksonville sea port in Jacksonville, Florida. On August 20, 2004, DHS published a Notice in the **Federal Register** at 69 FR 51695 adding certain ports to, and deleting certain ports from, inclusion in the US–VISIT program. In this Notice, the Jacksonville sea port in Jacksonville, Florida was inadvertently deleted.

What Does This Notice Do?

This Notice amends the Notice published on August 20, 2004 to include the Jacksonville sea port on the list of ports of entry designated to collect biometric data from certain aliens upon arrival in the United States. No other action is taken in this Notice.

Notice of Requirements for Biometric Collection From Aliens

DHS hereby designates the following ports of entry for inclusion in US–VISIT for the collection of information at the time of alien arrival pursuant to 8 CFR 235.1(d)(1):

Sea ports: Jacksonville, Florida.

Dated: August 23, 2004.

Tom Ridge,

Secretary of Homeland Security.

[FR Doc. 04–19553 Filed 8–25–04; 8:45 am]

BILLING CODE 4410–10–P

DEPARTMENT OF HOMELAND SECURITY

Bureau of Customs and Border Protection

Departmental Advisory Committee on Commercial Operations of the Bureau of Customs and Border Protection and Related Functions (COAC)

AGENCY: Bureau of Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of meeting.

SUMMARY: This notice announces the date, time, and location for the final meeting of the eighth term of the Departmental Advisory Committee on Commercial Operations of the Bureau of Customs and Border Protection and Related Functions (COAC), and the expected agenda for its consideration.

DATES: The next meeting of the COAC will be held on Friday, September 10, 2004, 9 a.m. to 1 p.m.

ADDRESSES: The meeting of the Departmental Advisory Committee on Commercial Operations of the Bureau of Customs and Border Protection and Related Functions (COAC) will be held 9 a.m.–1 p.m. in the Adam's Mark Fountain Room, Adam's Mark Hotel, 120 Church Street, Buffalo, NY 14202; hotel ph: (716) 845–5100/fax: (716) 845–5377.

FOR FURTHER INFORMATION CONTACT: Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone 571–227–3977; facsimile 571–227–1937.

SUPPLEMENTARY INFORMATION: This meeting is open to the public; however, participation in COAC deliberations is limited to COAC members, Homeland Security and Treasury Department officials, and persons invited to attend the meeting for special presentations. Since seating is limited, all persons attending this meeting should provide notice to Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone 571–227–3977; facsimile 571–227–1937, no later than 2 p.m. e.s.t. on Tuesday, September 7, 2004.

Information on Services for Individuals with Disabilities: For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone 571–227–3977; facsimile 571–227–1937, as soon as possible.

Draft Agenda: The COAC is expected to pursue the following agenda, which may be modified prior to the meeting:

1. MTSA Subcommittee
2. Security Subcommittee
   a. Advance Cargo Information
   b. WCO Security
   c. C–TPAT Process Review
3. Automation Issues
   a. ACE funding and development schedule
   b. ACS downtime
4. International Trade Data System (ITDS)
5. Agriculture Subcommittee
6. Creation of Infrastructure Subcommittee
7. Bioterrorism Act
8. Focused Assessment Program

Dated: August 23, 2004.

C. Stewart Verdery, Jr.,

Assistant Secretary for Border and Transportation Security Policy and Planning.

[FR Doc. 04–19505 Filed 8–25–04; 8:45 am]

BILLING CODE 4410–10–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4907–N–27]

Notice of Proposed Information Collection: Comment Request; Application for Approval—FHA Lender and/or Ginnie Mae Mortgage-Backed Securities Issuer Branch Office Notification—Title I/Title II

AGENCY: Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork